Publications by authors named "Susan Asirvatham"
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
Jumoke Okikiolu Claire Woodley Llywelyn Cadman-Davies Jennifer O'Sullivan Deepti Radia Susan Asirvatham
Leuk Res Rep
December 2022
Article Synopsis
- Pegylated interferons, particularly peginterferon alfa-2a, are commonly used to treat Myeloproliferative Neoplasms (MPN), but a newer drug called ropeginterferon alfa-2b (ropegIFN) has emerged as an option, especially for Polycythaemia Vera (PV).
- RopegIFN received a recommendation from the European Medicine Authority (EMA) and FDA approval in November 2021 after positive results from Phase III trials.
- The study highlights the safety and tolerability of ropegIFN in MPN patients, confirming its efficacy in treating PV and its potential use during pregnancy.
Article Synopsis
- - The study investigates potential new treatment options for chronic myeloid leukaemia (CML) to enhance effectiveness for patients who don't respond to current therapies and to assess if some patients can stop taking tyrosine kinase inhibitors (TKIs).
- - Findings show that at diagnosis, there is a higher presence of regulatory T cells (Tregs) and markers of T-cell exhaustion, particularly in patients with advanced disease.
- - Increased levels of inflammatory cytokines, such as TNF-a and IL-6, were found in the plasma of newly diagnosed patients, indicating a heightened inflammatory response likely due to the accumulation of cancer-related antigens.
Article Synopsis
- Supplemental Digital Content can enhance the main text by providing additional information or resources.
- It may include things like videos, charts, or interactive elements to improve understanding.
- This extra content is often accessible online and complements the primary material for better learning.